457 related articles for article (PubMed ID: 28408211)
1. Cardiac voltage-gated ion channels in safety pharmacology: Review of the landscape leading to the CiPA initiative.
Huang H; Pugsley MK; Fermini B; Curtis MJ; Koerner J; Accardi M; Authier S
J Pharmacol Toxicol Methods; 2017 Sep; 87():11-23. PubMed ID: 28408211
[TBL] [Abstract][Full Text] [Related]
2. CSAHi study: Detection of drug-induced ion channel/receptor responses, QT prolongation, and arrhythmia using multi-electrode arrays in combination with human induced pluripotent stem cell-derived cardiomyocytes.
Kitaguchi T; Moriyama Y; Taniguchi T; Maeda S; Ando H; Uda T; Otabe K; Oguchi M; Shimizu S; Saito H; Toratani A; Asayama M; Yamamoto W; Matsumoto E; Saji D; Ohnaka H; Miyamoto N
J Pharmacol Toxicol Methods; 2017; 85():73-81. PubMed ID: 28163191
[TBL] [Abstract][Full Text] [Related]
3. CiPA challenges and opportunities from a non-clinical, clinical and regulatory perspectives. An overview of the safety pharmacology scientific discussion.
Wallis R; Benson C; Darpo B; Gintant G; Kanda Y; Prasad K; Strauss DG; Valentin JP
J Pharmacol Toxicol Methods; 2018; 93():15-25. PubMed ID: 29958940
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive in vitro Proarrhythmia Assay, a novel in vitro/in silico paradigm to detect ventricular proarrhythmic liability: a visionary 21st century initiative.
Cavero I; Holzgrefe H
Expert Opin Drug Saf; 2014 Jun; 13(6):745-58. PubMed ID: 24845945
[TBL] [Abstract][Full Text] [Related]
5.
Boulay E; Troncy E; Jacquemet V; Huang H; Pugsley MK; Downey AM; Venegas Baca R; Authier S
Int J Toxicol; 2024; 43(4):357-367. PubMed ID: 38477622
[No Abstract] [Full Text] [Related]
6. The Comprehensive in Vitro Proarrhythmia Assay (CiPA) initiative - Update on progress.
Colatsky T; Fermini B; Gintant G; Pierson JB; Sager P; Sekino Y; Strauss DG; Stockbridge N
J Pharmacol Toxicol Methods; 2016; 81():15-20. PubMed ID: 27282641
[TBL] [Abstract][Full Text] [Related]
7. An evaluation of 30 clinical drugs against the comprehensive in vitro proarrhythmia assay (CiPA) proposed ion channel panel.
Crumb WJ; Vicente J; Johannesen L; Strauss DG
J Pharmacol Toxicol Methods; 2016; 81():251-62. PubMed ID: 27060526
[TBL] [Abstract][Full Text] [Related]
8. Recording of multiple ion current components and action potentials in human induced pluripotent stem cell-derived cardiomyocytes via automated patch-clamp.
Mann SA; Heide J; Knott T; Airini R; Epureanu FB; Deftu AF; Deftu AT; Radu BM; Amuzescu B
J Pharmacol Toxicol Methods; 2019; 100():106599. PubMed ID: 31228558
[TBL] [Abstract][Full Text] [Related]
9. Comparative pharmacology of guinea pig cardiac myocyte and cloned hERG (I(Kr)) channel.
Davie C; Pierre-Valentin J; Pollard C; Standen N; Mitcheson J; Alexander P; Thong B
J Cardiovasc Electrophysiol; 2004 Nov; 15(11):1302-9. PubMed ID: 15574182
[TBL] [Abstract][Full Text] [Related]
10. Impact of disease state on arrhythmic event detection by action potential modelling in cardiac safety pharmacology.
Christophe B; Crumb WJ
J Pharmacol Toxicol Methods; 2019; 96():15-26. PubMed ID: 30580044
[TBL] [Abstract][Full Text] [Related]
11. CiPA: Ongoing testing, future qualification procedures, and pending issues.
Cavero I; Holzgrefe H
J Pharmacol Toxicol Methods; 2015; 76():27-37. PubMed ID: 26159293
[TBL] [Abstract][Full Text] [Related]
12. A New Perspective in the Field of Cardiac Safety Testing through the Comprehensive In Vitro Proarrhythmia Assay Paradigm.
Fermini B; Hancox JC; Abi-Gerges N; Bridgland-Taylor M; Chaudhary KW; Colatsky T; Correll K; Crumb W; Damiano B; Erdemli G; Gintant G; Imredy J; Koerner J; Kramer J; Levesque P; Li Z; Lindqvist A; Obejero-Paz CA; Rampe D; Sawada K; Strauss DG; Vandenberg JI
J Biomol Screen; 2016 Jan; 21(1):1-11. PubMed ID: 26170255
[TBL] [Abstract][Full Text] [Related]
13. Multi-parametric assessment of cardiomyocyte excitation-contraction coupling using impedance and field potential recording: A tool for cardiac safety assessment.
Zhang X; Guo L; Zeng H; White SL; Furniss M; Balasubramanian B; Lis E; Lagrutta A; Sannajust F; Zhao LL; Xi B; Wang X; Davis M; Abassi YA
J Pharmacol Toxicol Methods; 2016; 81():201-16. PubMed ID: 27282640
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of nefazodone-induced cardiotoxicity in human induced pluripotent stem cell-derived cardiomyocytes.
Lee S; Lee HA; Choi SW; Kim SJ; Kim KS
Toxicol Appl Pharmacol; 2016 Apr; 296():42-53. PubMed ID: 26821276
[TBL] [Abstract][Full Text] [Related]
15. Proarrhythmia liability assessment and the comprehensive in vitro Proarrhythmia Assay (CiPA): An industry survey on current practice.
Authier S; Pugsley MK; Koerner JE; Fermini B; Redfern WS; Valentin JP; Vargas HM; Leishman DJ; Correll K; Curtis MJ
J Pharmacol Toxicol Methods; 2017 Jul; 86():34-43. PubMed ID: 28223123
[TBL] [Abstract][Full Text] [Related]
16. Biophysics and Molecular Biology of Cardiac Ion Channels for the Safety Pharmacologist.
Pugsley MK; Curtis MJ; Hayes ES
Handb Exp Pharmacol; 2015; 229():149-203. PubMed ID: 26091640
[TBL] [Abstract][Full Text] [Related]
17. Azithromycin Causes a Novel Proarrhythmic Syndrome.
Yang Z; Prinsen JK; Bersell KR; Shen W; Yermalitskaya L; Sidorova T; Luis PB; Hall L; Zhang W; Du L; Milne G; Tucker P; George AL; Campbell CM; Pickett RA; Shaffer CM; Chopra N; Yang T; Knollmann BC; Roden DM; Murray KT
Circ Arrhythm Electrophysiol; 2017 Apr; 10(4):. PubMed ID: 28408648
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive Translational Assessment of Human-Induced Pluripotent Stem Cell Derived Cardiomyocytes for Evaluating Drug-Induced Arrhythmias.
Blinova K; Stohlman J; Vicente J; Chan D; Johannesen L; Hortigon-Vinagre MP; Zamora V; Smith G; Crumb WJ; Pang L; Lyn-Cook B; Ross J; Brock M; Chvatal S; Millard D; Galeotti L; Stockbridge N; Strauss DG
Toxicol Sci; 2017 Jan; 155(1):234-247. PubMed ID: 27701120
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive In Vitro Proarrhythmia Assay (CiPA) Update from a Cardiac Safety Research Consortium / Health and Environmental Sciences Institute / FDA Meeting.
Strauss DG; Gintant G; Li Z; Wu W; Blinova K; Vicente J; Turner JR; Sager PT
Ther Innov Regul Sci; 2019 Jul; 53(4):519-525. PubMed ID: 30157676
[TBL] [Abstract][Full Text] [Related]
20. Early drug development: assessment of proarrhythmic risk and cardiovascular safety.
Lester RM; Olbertz J
Expert Rev Clin Pharmacol; 2016 Dec; 9(12):1611-1618. PubMed ID: 27718759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
